tiprankstipranks
Trending News
More News >
WORK Medical Technology Group LTD (WOK)
NASDAQ:WOK
US Market
Advertisement

WORK Medical Technology Group LTD (WOK) AI Stock Analysis

Compare
23 Followers

Top Page

WOK

WORK Medical Technology Group LTD

(NASDAQ:WOK)

Select Model
Select Model
Select Model
Neutral 49 (OpenAI - 4o)
Rating:49Neutral
Price Target:
$1.00
▲(25.00% Upside)
The overall stock score is primarily impacted by the company's poor financial performance, characterized by declining revenues and operational inefficiencies. Technical analysis shows some neutral to slightly positive signals, but the lack of valuation metrics and absence of earnings call data limit further insights.

WORK Medical Technology Group LTD (WOK) vs. SPDR S&P 500 ETF (SPY)

WORK Medical Technology Group LTD Business Overview & Revenue Model

Company DescriptionWORK Medical Technology Group LTD, together with its subsidiaries, manufactures and sells medical consumables in the People's Republic of China and internationally. The company offers disposable medical devices, such as medical face masks, artery compression tourniquets, endotracheal tube holders, intubating stylets, and guedel airways, etc.; disposable breathing circuits, laryngeal mask airways, endotracheal tubes, anesthetic kits, oxygen face masks, heat and moisture exchanging filters, anesthesia masks, laryngoscope blades, suction sets, and nasal oxygen cannulas; other medical devices, such as KN95 masks and filtering half mask; and visualized prostatic dilatation catheters. It also exports its products to approximately 30 countries in Asia, Africa, Europe, North America, South America, and Oceania. WORK Medical Technology Group LTD was founded in 2002 and is based in Hangzhou City, China.
How the Company Makes MoneyWORK Medical Technology Group LTD generates revenue through a diverse array of channels. The primary source of income is the sale of its medical devices and software solutions to healthcare institutions and professionals. The company also offers subscription-based models for its software products, which provide continuous updates and support, ensuring recurring revenue. Additionally, WOK engages in strategic partnerships with healthcare providers and technology companies to expand its market reach and enhance its product offerings, further contributing to its revenue streams.

WORK Medical Technology Group LTD Financial Statement Overview

Summary
WORK Medical Technology Group LTD faces significant financial challenges, with declining revenues, operational inefficiencies, and high leverage. The company's inability to generate positive cash flow from operations and reliance on external financing pose risks to its financial health.
Income Statement
35
Negative
The company has experienced a significant decline in revenue over the past few years, with a negative revenue growth rate from 2020 to 2024. Gross profit margin has decreased, and the company is currently operating at a net loss, indicating challenges in maintaining profitability. The negative EBIT and EBITDA margins further highlight operational inefficiencies.
Balance Sheet
45
Neutral
The balance sheet shows a high level of debt relative to equity, with a debt-to-equity ratio indicating potential leverage risks. The equity ratio is moderate, suggesting a balanced asset structure. However, the negative return on equity reflects poor profitability, impacting overall financial stability.
Cash Flow
30
Negative
The cash flow statement reveals negative free cash flow growth, indicating difficulties in generating cash from operations. The operating cash flow to net income ratio is negative, suggesting inefficiencies in converting income into cash. The company relies heavily on financing activities to sustain operations.
BreakdownTTMDec 2024Dec 2023Dec 2022Dec 2021Dec 2020
Income Statement
Total Revenue11.51M11.51M13.57M19.71M45.86M52.53M
Gross Profit2.87M2.87M4.14M4.42M8.64M10.85M
EBITDA-2.65M-2.65M2.08M4.72M11.87M4.75M
Net Income-3.49M-3.49M112.03K865.21K5.96M1.16M
Balance Sheet
Total Assets36.25M36.25M29.96M25.54M30.66M56.20M
Cash, Cash Equivalents and Short-Term Investments6.56M6.56M1.60M731.18K508.71K200.40K
Total Debt13.47M13.47M9.10M6.30M6.60M4.05M
Total Liabilities20.18M20.18M18.97M14.35M19.26M50.27M
Stockholders Equity13.19M13.19M9.88M10.00M10.04M4.90M
Cash Flow
Free Cash Flow-11.45M-11.49M1.63M-4.27M-7.24M9.65M
Operating Cash Flow-2.23M-2.23M2.21M-2.26M-7.18M27.20M
Investing Cash Flow-9.06M-9.06M-583.30K-1.35M-60.00K-16.84M
Financing Cash Flow15.66M15.66M-728.72K3.57M7.99M-10.28M

WORK Medical Technology Group LTD Technical Analysis

Technical Analysis Sentiment
Positive
Last Price0.80
Price Trends
50DMA
0.79
Positive
100DMA
0.73
Positive
200DMA
1.67
Negative
Market Momentum
MACD
<0.01
Negative
RSI
55.76
Neutral
STOCH
46.65
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For WOK, the sentiment is Positive. The current price of 0.8 is above the 20-day moving average (MA) of 0.79, above the 50-day MA of 0.79, and below the 200-day MA of 1.67, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 55.76 is Neutral, neither overbought nor oversold. The STOCH value of 46.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for WOK.

WORK Medical Technology Group LTD Peers Comparison

Overall Rating
UnderperformOutperform
Sector (51)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
71
Outperform
13.54M1.176.82%-0.19%-18.41%
49
Neutral
$45.23M
46
Neutral
45.59M-6.68-208.80%7.84%-43.00%
44
Neutral
15.77M-0.42-816.54%98.61%-1.98%
51
Neutral
$7.86B-0.30-43.30%2.27%22.53%-2.21%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
WOK
WORK Medical Technology Group LTD
0.80
-3.40
-80.95%
MLSS
Milestone Scientific
0.58
-0.33
-36.26%
MBOT
Microbot Medical
3.34
2.40
255.32%
FEMY
Femasys
0.37
-0.72
-66.06%
MHUA
Meihua International Medical Technologies Co., Ltd.
0.41
-0.70
-63.06%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Sep 10, 2025